Expert Ratings For Caribou Biosciences
Portfolio Pulse from Benzinga Insights
Caribou Biosciences (NASDAQ:CRBU) has received mixed analyst ratings over the past three months, with a majority being bullish. Analysts have maintained their price targets, with an average of $10.25. Despite this, the company faces financial challenges, including a decline in revenue growth and below-average profitability metrics.
September 03, 2024 | 5:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Caribou Biosciences has received mostly bullish analyst ratings, with a stable average price target of $10.25. However, the company faces financial challenges, including a decline in revenue growth and low profitability metrics.
The majority of analysts are bullish on CRBU, maintaining a stable price target, which suggests confidence in the stock's potential. However, the company's financial challenges, such as declining revenue and low profitability, may offset positive sentiment, leading to a neutral short-term impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100